New drug access for prostate cancer patients before market launch
NCT ID NCT03523338
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 21 times
Summary
This study offers apalutamide to men whose prostate cancer has stopped responding to hormone therapy but has not yet spread. The goal is to collect safety information until the drug becomes widely available. Participants must have rising PSA levels and continue their current hormone treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centro Oncologico Estatal ISSEMYM
Toluca, 50180, Mexico
-
Ensino e Terapia de Inovacao Clinica AMO Etica
Salvador, 41950 640, Brazil
-
Farmaco Oncología especializada S.A. de C.V
Zapopan, 45050, Mexico
-
Fundacao Antonio Prudente A C Camargo Cancer Center
São Paulo, 01509 900, Brazil
-
Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
São Paulo, 01246 000, Brazil
-
Hospital Pablo Tobon Uribe
Medellín, 050034, Colombia
-
Instituto Nacional de Cancerologia
México, 14080, Mexico
-
Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
Rio de Janeiro, 22775 001, Brazil
-
Núcleo de Pesquisa São Camilo
São Paulo, 04014-002, Brazil
-
Oncologia Integral Satelite
Naucalpan, 53100, Mexico
-
Ynova Pesquisa Clinica
Florianópolis, 88020-210, Brazil
-
i Can Oncology Center
Monterrey, 64710, Mexico
Conditions
Explore the condition pages connected to this study.